Market Overview

UPDATE: Stifel Nicolaus Initiates Covidien at Hold on Pending Spin-Off

Share:
Related COV
Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression
Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids

Stifel Nicolaus initiated coverage on Covidien (NYSE: COV) with a Hold rating.

Stifel Nicolaus said, "In our view, there is very little one can find in the Covidien story that is not to like. Since the company's spin-off from Tyco five years ago, Covidien has set clear financial and operating goals and delivered on them with accelerating organic growth in its key business lines and significant gross margin expansion. Looking ahead, we think COV is poised for continued growth above its large-cap MedTech peers. However, a reasonable valuation and the potential for incremental pharma spin-off related dilution keep us on the sidelines."

Covidien closed at $56.17 on Monday.

Latest Ratings for COV

DateFirmActionFromTo
Nov 2014JefferiesMaintainsBuy
Oct 2014Morgan StanleyDowngradesOverweightEqual-weight
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for COV
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (COV)

View Comments and Join the Discussion!